Two Sigma Investments
NGNE icon

Two Sigma Investments’s Neurogene NGNE Stock Holding History

Two Sigma Investments’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Buy
13,891
+1,900
+16% +$36.8K ﹤0.01% 4117
2025
Q4 		$247K Sell
11,991
-8,560
-42% -$213K ﹤0.01% 3677
2025
Q3 		$356K Buy
20,551
+54
+0.3% +$1.08K ﹤0.01% 3140
2025
Q2 		$306K Buy
20,497
+9,653
+89% +$151K ﹤0.01% 2784
2025
Q1 		$127K Sell
10,844
-9,785
-47% -$170K ﹤0.01% 2933
2024
Q4 		$472K Buy
+20,629
New +$768K ﹤0.01% 2566
2024
Q2 		– Sell
-3,961
Closed -$202K – 3222
2024
Q1 		$202K Buy
+3,961
New +$132K ﹤0.01% 2716
2023
Q4 		– Sell
-8,552
Closed -$135K – 3298
2023
Q3 		$135K Sell
8,552
-2,008
-19% -$29.6K ﹤0.01% 2711
2023
Q2 		$175K Sell
10,560
-775
-7% -$12.7K ﹤0.01% 2670
2023
Q1 		$159K Sell
11,335
-3,617
-24% -$42.4K ﹤0.01% 2604
2022
Q4 		$152K Sell
14,952
-2,205
-13% -$22.8K ﹤0.01% 2444
2022
Q3 		$220K Buy
17,157
+1,533
+10% +$31.3K ﹤0.01% 2078
2022
Q2 		$322K Buy
15,624
+3,425
+28% +$83.5K ﹤0.01% 2003
2022
Q1 		$459K Buy
12,199
+4,404
+56% +$257K ﹤0.01% 2061
2021
Q4 		$751K Buy
7,795
+1,784
+30% +$217K ﹤0.01% 2828
2021
Q3 		$869K Buy
6,011
+4,056
+207% +$621K ﹤0.01% 2736
2021
Q2 		$361K Buy
1,955
+1,211
+163% +$268K ﹤0.01% 3356
2021
Q1 		$183K Sell
744
-7,693
-91% -$1.97M ﹤0.01% 3645
2020
Q4 		$2.38M Buy
8,437
+1,120
+15% +$274K 0.01% 1385
2020
Q3 		$1.76M Buy
7,317
+2,807
+62% +$680K 0.01% 1381
2020
Q2 		$1.5M Buy
4,510
+2,576
+133% +$671K 0.01% 1261
2020
Q1 		$440K Buy
1,934
+1,249
+182% +$257K ﹤0.01% 2033
2019
Q4 		$169K Sell
685
-2,633
-79% -$262K ﹤0.01% 3461
2019
Q3 		$189K Sell
3,318
-1,287
-28% -$78.5K ﹤0.01% 3206
2019
Q2 		$217K Sell
4,605
-1,490
-24% -$76.6K ﹤0.01% 3048
2019
Q1 		$329K Sell
6,095
-576
-9% -$29.1K ﹤0.01% 2537
2018
Q4 		$288K Sell
6,671
-735
-10% -$35.8K ﹤0.01% 2480
2018
Q3 		$434K Buy
+7,406
New +$437K ﹤0.01% 2557

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Two Sigma Investments's NGNE Position: Q1 2026 in Review

Two Sigma Investments increased its Neurogene (NGNE) stake by 16% in Q1 2026, buying an estimated $36.8K and bringing the position to 13,891 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #4117.

Two Sigma Investments first reported a position in NGNE in Q3 2018 and has held it in 28 quarters since. The position peaked at $2.38M in Q4 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Two Sigma Investments held 13,891 shares of Neurogene worth $280K as of Q1 2026.
  • Two Sigma Investments bought 1,900 Neurogene shares in Q1 2026, an estimated $36.8K.
  • Neurogene made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4117 holding.
  • Two Sigma Investments first reported a position in Neurogene in Q3 2018 and has held it in 28 quarters since.
  • Two Sigma Investments's Neurogene position peaked at $2.38M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.